达巴万星作为革兰阳性菌感染性心内膜炎的初始和序贯治疗：维也纳总医院 2 年经验。
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.
机构信息
Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria.
Institute for Infectious Diseases and Infection Control, Jena University Hospital.
出版信息
Clin Infect Dis. 2018 Aug 16;67(5):795-798. doi: 10.1093/cid/ciy279.
PMID:29659732
Abstract
The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.
摘要
回顾性评估了达巴万星作为革兰阳性菌菌血症合并感染性心内膜炎的一线和序贯治疗的临床疗效和安全性。临床成功率很高（92.6%），但在 27 例患者中，有 24 例仅在清除血流中的细菌后才使用达巴万星。
Zotero 插件